The results showed a significant increase in tumor-infiltrating T lymphocytes in patients with clear cell carcinoma in the combination therapy group compared to anti-CTLA-4 monotherapy, while no similar phenomenon was observed in patients with non-clear cell carcinoma. The gene discussed is CTLA4; the disease is clear cell adenocarcinoma.